Trial record 1 of 1 for: EoE and Novartis
Previous Study | Return to List | Next Study
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: November 25, 2009
Last updated: November 21, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||No date given|
|Primary Completion Date:||February 2012 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||October 29, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. doi: 10.1016/j.jaci.2014.07.049. Epub 2014 Sep 13.